Publications by authors named "Deanna A Mele"

Claim this Profile
S
Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitors.
Anthony J Metrano, Lucas A Morrill, Gayathri Bommakanti, Robert Casella, Steve Cook, Deanna A Mele

RSC Med Chem· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor.
Jason D Shields, David Baker, Amber Y S Balazs, Gayathri Bommakanti, Robert Casella, Deanna A Mele

J Med Chem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay.
Tristan Tay, Gayathri Bommakanti, Elizabeth Jaensch, Aparna Gorthi, Iswarya Karapa Reddy, Deanna A Mele

Cell Rep Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners.
Aatman S Doshi, Susan Cantin, Marylens Hernandez, Srimathi Srinivasan, Sharon Tentarelli, Deanna A Mele

Mol Cancer Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy.
Aatman S Doshi, Susan Cantin, Laura B Prickett, Deanna A Mele, Mansoor Amiji

J Control Release· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Alexey Revenko, Larissa S Carnevalli, Charles Sinclair, Ben Johnson, Alison Peter, Deanna A Mele

J Immunother Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer Immunotherapy.
Daniel H O' Donovan, Yumeng Mao, Deanna A Mele

Curr Med Chem· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.
Theresa A Proia, Maneesh Singh, Richard Woessner, Larissa Carnevalli, Gayathri Bommakanti, Deanna A Mele

Clin Cancer Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule AZD4635 inhibitor of AR signaling rescues immune cell function including CD103 dendritic cells enhancing anti-tumor immunity.
Alexandra Borodovsky, Christine M Barbon, Yanjun Wang, Minwei Ye, Laura Prickett, Deanna A Mele

J Immunother Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity.
Sophie Langdon, Adina Hughes, Molly A Taylor, Elizabeth A Kuczynski, Deanna A Mele

Oncoimmunology· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BET bromodomain inhibition suppresses TH17-mediated pathology.
Deanna A Mele, Andres Salmeron, Srimoyee Ghosh, Hon-Ren Huang, Barbara M Bryant

J Exp Med· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting MYC dependence in cancer by inhibiting BET bromodomains.
Jennifer A Mertz, Andrew R Conery, Barbara M Bryant, Peter Sandy, Srividya Balasubramanian, Deanna A Mele

Proc Natl Acad Sci U S A· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Th17 differentiation is the default program for DPP2-deficient T-cell differentiation.
Deanna A Mele, James F Sampson, Brigitte T Huber

Eur J Immunol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurogenin 3-specific dipeptidyl peptidase-2 deficiency causes impaired glucose tolerance, insulin resistance, and visceral obesity.
Olga V Danilova, Albert K Tai, Deanna A Mele, Martin Beinborn, Andrew B Leiter

Endocrinology· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dipeptidyl peptidase 2 is an essential survival factor in the regulation of cell quiescence.
Deanna A Mele, Pradeep Bista, Diana Velez Baez, Brigitte T Huber

Cell Cycle· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphocyte quiescence factor Dpp2 is transcriptionally activated by KLF2 and TOB1.
Pradeep Bista, Deanna A Mele, Diana Velez Baez, Brigitte T Huber

Mol Immunol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis